List of Isentress drug patents
Isentress is owned by Merck Sharp Dohme.
Isentress contains Raltegravir Potassium.
Isentress has a total of 11 drug patents out of which 2 drug patents have expired.
Expired drug patents of Isentress are:
- US7217713
- US7435734
Isentress was authorised for market use on 20 December, 2013.
Isentress is available in powder;oral dosage forms.
Isentress can be used as treatment of hiv infection, treatment of hiv-1 infection.
The generics of Isentress are possible to be released after 30 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months from now) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(4 months ago) | |
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(4 months ago) | |
|
US7435734
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(29 days from now) | |
|
US7217713
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(29 days from now) | |
|
US7169780
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 12 days from now) | |
|
US7754731
(Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(6 years from now) | |
| US9649311 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(7 years from now) | |
|
US9649311
(Pediatric) | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(8 years from now) | |
| US10772888 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(9 years from now) | |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection
Dosage: POWDER;ORAL
ISENTRESS family patents
17
United States
6
China
5
European Union
4
Spain
4
New Zealand
4
Norway
4
Korea, Republic of
4
Japan
3
Portugal
3
Germany
3
Brazil
3
Croatia
3
Austria
3
Mexico
3
South Africa
3
Canada
3
Hungary
3
Slovenia
3
Israel
3
Poland
3
Australia
3
Denmark
2
Malaysia
2
Colombia
2
Argentina
2
Hong Kong
2
EA
2
Lithuania
2
ME
2
Ukraine
2
Georgia
2
RS
1
United Kingdom
1
Russia
1
Costa Rica
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Tunisia
1
India
1
Nicaragua
1
Cyprus
1
Luxembourg
1
Iceland
1
Yugoslavia
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic